NYSE:ZBH - New York Stock Exchange, Inc. - US98956P1021 - Common Stock - Currency: USD
Zimmer Biomet beat Q4 estimates with $2.02 billion in sales and $2.31 EPS.
Mentions: FNA
Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.3% year on year to $2.02 billion. Its non-GAAP profit of $2.31 per share was 0.8% above analysts’ consensus estimates.
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Paragon 28, Inc. (NYSE: FNA) and its board of directors concerning the...
Mentions: FNA
Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know.
The robotic-assisted surgery trend is accelerating and Intuitive Surgical continues to lead the pack as its continued to keeps its wide moat since 2000.
Tesla upgraded, MongoDB initiated: Wall Street's top analyst calls
Medtronic (MDT) and Zimmer Biomet (ZBH) are emerging as serious contenders in robotic surgery, challenging Intuitive Surgical’s (ISRG) market dominance.
The company is well known for its hip and knee replacements. Full-year sales will take an unexpected hit.
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision...
ZBH stock results show that Zimmer Biomet Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
At their 52-week lows, these undervalued healthcare stocks present a favorable return supported by healthcare spending tailwinds.